IGC Pharma Strengthens CALMA Trial Through Caregiver Outreach
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
